Among these genes, AP3B1, ONECUT2 and IL-6 were already confirmed to be direct targets of miR-9 in breast cancer, insulin-producing cells, and cervical adenocarcinoma, respectively [15–17], which demonstrated the reliability of our screening strategy. This evidence concerns the gene INS and breast cancer.